VRDN Stock Summary and Trading Ideas (Viridian Therapeutics | NASDAQ:VRDN)

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.

As of September 23, 2026, VRDN stock price declined to $21.43 with 2,766,032 million shares trading.

VRDN has a beta of -0.17, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.00 to the broad based SPY ETF.

VRDN has a market cap of $2.43 billion. This is considered a Mid Cap stock.

Last quarter Viridian Therapeutics reported $233,000 in Revenue and -$1.05 earnings per share. This beat revenue expectation by $211,000 and missed earnings estimates by -$.03.

In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.

The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, XBI, VXF, SCHA, VTWO.

VRDN has underperformed the market in the last year with a price return of +9.6% while the SPY ETF gained +16.9%. However, in the short term, VRDN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +24.0% vs +4.9% return in SPY. But in the last 2 weeks, VRDN shares have been beat by the market, returning -5.7% compared to an SPY return of +1.0%.

VRDN support price is $21.50 and resistance is $22.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.